Cervomed Inc. (CRVO) has disclosed a new risk, in the Manufacturing category.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cervomed Inc. faces the risk that changes in manufacturing methods or formulation for product candidates like neflamapimod could drive up development costs and delay regulatory approval. Such changes may alter clinical performance and force additional or bridging trials, extending timelines and jeopardizing commercialization and revenue generation prospects.
Overall, Wall Street has a Strong Buy consensus rating on CRVO stock based on 5 Buys.
To learn more about Cervomed Inc.’s risk factors, click here.